

Sylvain Audia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8029583/publications.pdf>

Version: 2024-02-01

98
papers

3,612
citations

147801

31
h-index

149698

56
g-index

123
all docs

123
docs citations

123
times ranked

4374
citing authors

#	ARTICLE	IF	CITATIONS
1	Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 2499-2503.	6.7	302
2	Pathogenesis of immune thrombocytopenia. <i>Autoimmunity Reviews</i> , 2017, 16, 620-632.	5.8	249
3	Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3788-3798.	6.7	181
4	Recent advances in our understanding of giant cell arteritis pathogenesis. <i>Autoimmunity Reviews</i> , 2017, 16, 833-844.	5.8	150
5	Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. <i>Blood</i> , 2014, 124, 3228-3236.	1.4	142
6	Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. <i>Neurology</i> , 2020, 95, e70-e78.	1.1	142
7	The Reversed Halo Sign: Pathognomonic Pattern of Pulmonary Mucormycosis in Leukemic Patients With Neutropenia?. <i>Clinical Infectious Diseases</i> , 2014, 58, 672-678.	5.8	133
8	Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes. <i>Clinical and Experimental Immunology</i> , 2007, 150, 523-530.	2.6	104
9	Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. <i>Blood</i> , 2011, 118, 4394-4400.	1.4	98
10	Stroke associated with giant cell arteritis: a population-based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 216-221.	1.9	95
11	A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm autoimmune hemolytic anemia in adults (the RAIHA study). <i>American Journal of Hematology</i> , 2017, 92, 23-27.	4.1	84
12	T Cell Polarization toward TH2/TFH2 and TH17/TFH17 in Patients with IgG4-Related Disease. <i>Frontiers in Immunology</i> , 2017, 8, 235.	4.8	81
13	A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. <i>Haematologica</i> , 2013, 98, 881-887.	3.5	78
14	Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. <i>Blood</i> , 2016, 128, 1625-1630.	1.4	78
15	Ophthalmic manifestations in IgG4-related disease. <i>Medicine (United States)</i> , 2017, 96, e6205.	1.0	65
16	Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. <i>Blood</i> , 2014, 124, 2858-2866.	1.4	64
17	Peroxynitrite-Dependent Killing of Cancer Cells and Presentation of Released Tumor Antigens by Activated Dendritic Cells. <i>Journal of Immunology</i> , 2010, 184, 1876-1884.	0.8	58
18	Involvement and prognosis value of CD8 + T cells in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2016, 72, 73-83.	6.5	56

#	ARTICLE	IF	CITATIONS
19	Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. <i>American Journal of Hematology</i> , 2019, 94, 1314-1324.	4.1	55
20	Evans™ Syndrome: From Diagnosis to Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 3851.	2.4	50
21	Venous thromboembolic events during warm autoimmune hemolytic anemia. <i>PLoS ONE</i> , 2018, 13, e0207218.	2.5	49
22	Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments. <i>HemaSphere</i> , 2021, 5, e574.	2.7	45
23	Preferential splenic CD8+ T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. <i>Blood</i> , 2013, 122, 2477-2486.	1.4	42
24	Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. <i>Journal of Autoimmunity</i> , 2015, 62, 22-30.	6.5	40
25	Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	40
26	Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. <i>Joint Bone Spine</i> , 2011, 78, 241-245.	1.6	39
27	Clinical Spectrum, Treatment, and Outcome of Patients with Type II Mixed Cryoglobulinemia without Evidence of Hepatitis C Infection. <i>Journal of Rheumatology</i> , 2011, 38, 716-722.	2.0	38
28	Fc γ 3 receptor expression on splenic macrophages in adult immune thrombocytopenia. <i>Clinical and Experimental Immunology</i> , 2017, 188, 275-282.	2.6	38
29	Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. <i>Rheumatology</i> , 2018, 57, 1432-1438.	1.9	38
30	Severe Seoul hantavirus infection in a pregnant woman, France, October 2012. <i>Eurosurveillance</i> , 2013, 18, .	7.0	38
31	Etiologies and prognostic factors of leukocytoclastic vasculitis with skin involvement. <i>Medicine (United States)</i> , 2016, 95, e4238.	1.0	36
32	The inhibition of TNF- α anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. <i>Experimental Cell Research</i> , 2007, 313, 2345-2355.	2.6	35
33	B cell depleting therapy regulates splenic and circulating T follicular helper cells in immune thrombocytopenia. <i>Journal of Autoimmunity</i> , 2017, 77, 89-95.	6.5	33
34	Emerging Therapies in Immune Thrombocytopenia. <i>Journal of Clinical Medicine</i> , 2021, 10, 1004.	2.4	33
35	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
36	Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. <i>American Journal of Hematology</i> , 2013, 88, 858-861.	4.1	31

#	ARTICLE	IF	CITATIONS
37	Biological treatments in giant cell arteritis & Takayasu arteritis. <i>European Journal of Internal Medicine</i> , 2018, 50, 12-19.	2.2	30
38	Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory forkhead box protein 3 ⁺ positive CD8 ⁺ T lymphocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1614-1624.e4.	2.9	29
39	Diagnosis of hyperferritinemia in routine clinical practice. <i>Presse Medicale</i> , 2017, 46, e329-e338.	1.9	29
40	Tocilizumab as an add-on therapy to glucocorticoids during the first 3 ⁺ months of treatment of Giant cell arteritis: A prospective study. <i>European Journal of Internal Medicine</i> , 2018, 57, 96-104.	2.2	29
41	Bortezomib and dexamethasone, an original approach for treating multi ⁺ refractory warm autoimmune haemolytic anaemia. <i>British Journal of Haematology</i> , 2019, 187, 124-128.	2.5	29
42	Association of hidradenitis suppurativa and familial Mediterranean fever: A case series of 6 patients. <i>Joint Bone Spine</i> , 2017, 84, 159-162.	1.6	28
43	Is there still a place for ⁺ old therapies ⁺ in the management of immune thrombocytopenia?. <i>Revue De Medecine Interne</i> , 2016, 37, 43-49.	1.0	27
44	Observational Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase Deficiency. <i>Medicine (United States)</i> , 2016, 95, e3027.	1.0	24
45	Cytotoxic Dendritic Cells Generated from Cancer Patients. <i>Journal of Immunology</i> , 2011, 187, 2775-2782.	0.8	23
46	Endovascular stent placement for chronic post-thrombotic symptomatic ilio-femoral venous obstructive lesions: a single-center study of safety, efficacy and quality-of-life improvement. <i>Quantitative Imaging in Medicine and Surgery</i> , 2016, 6, 342-352.	2.0	23
47	Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review. <i>Journal of Rheumatology</i> , 2018, 45, 425-429.	2.0	23
48	HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. <i>Nature Communications</i> , 2018, 9, 1431.	12.8	21
49	Neutropenia in Felty's syndrome successfully treated with hydroxychloroquine. <i>Haematologica</i> , 2007, 92, e78-e79.	3.5	20
50	Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia. <i>Haematologica</i> , 2021, 106, 3198-3201.	3.5	20
51	Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1759-1763.	1.2	18
52	Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis. <i>Clinical and Translational Immunology</i> , 2021, 10, e1332.	3.8	18
53	Endovascular stenting for chronic femoro-iliac venous obstructive disease: Clinical efficacy and short-term outcomes. <i>Diagnostic and Interventional Imaging</i> , 2020, 101, 15-23.	3.2	17
54	Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia. <i>European Journal of Internal Medicine</i> , 2014, 25, 837-842.	2.2	16

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients. <i>PLoS ONE</i> , 2017, 12, e0187296.	2.5	15
56	Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study. <i>Internal Medicine Journal</i> , 2019, 49, 1154-1162.	0.8	15
57	Correction of Severe Myelofibrosis, Impaired Platelet Functions and Abnormalities in a Patient with Gray Platelet Syndrome Successfully Treated by Stem Cell Transplantation. <i>Platelets</i> , 2020, 31, 536-540.	2.3	13
58	Is TNF- α really involved in giant cell arteritis pathogenesis?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e1-e1.	0.9	11
59	High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia. <i>American Journal of Hematology</i> , 2021, 96, E43-E46.	4.1	11
60	Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia. <i>Journal of Clinical Medicine</i> , 2020, 9, 1998.	2.4	10
61	Myocardial infarction during giant cell arteritis: A cohort study. <i>European Journal of Internal Medicine</i> , 2021, 89, 30-38.	2.2	8
62	Splenic and Circulating Human T Follicular Helper Cell Regulation By B Cell Depleting Therapy during Immune Thrombocytopenia. <i>Blood</i> , 2015, 126, 8-8.	1.4	8
63	Pathogenesis of giant cell arteritis: new insight into the implication of CD161+ T cells. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, S65-73.	0.8	8
64	Severe cardiomyopathy revealing antineutrophil cytoplasmic antibodiesâ€negative eosinophilic granulomatosis with polyangiitis. <i>Internal Medicine Journal</i> , 2014, 44, 928-931.	0.8	7
65	Altered distribution and function of splenic innate lymphoid cells in adult chronic immune thrombocytopenia. <i>Journal of Autoimmunity</i> , 2018, 93, 139-144.	6.5	7
66	Safety and Efficacy of PRTX-100, a Highly Purified Form of Staphylococcal Protein A, in Patients with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2016, 128, 4929-4929.	1.4	7
67	Haemolyticâ€uraemic syndrome during severe lupus nephritis: efficacy of plasma exchange. <i>Internal Medicine Journal</i> , 2012, 42, 95-98.	0.8	6
68	Full-field optical coherence tomography for the diagnosis of giant cell arteritis. <i>PLoS ONE</i> , 2020, 15, e0234165.	2.5	6
69	Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect. <i>Oncolimmunology</i> , 2021, 10, 1880046.	4.6	6
70	AN UNUSUAL COMPLICATION OF ANTICOAGULATION THERAPY IN AN ELDERLY PATIENT: PITUITARY APOPLEXY WITH REMISSION OF ACROMEGALY. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1798-1800.	2.6	5
71	T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1. <i>BioMed Research International</i> , 2015, 2015, 1-10.	1.9	5
72	Mucosal-associated invariant T cells in Giant Cell Arteritis. <i>Journal of Autoimmunity</i> , 2021, 121, 102652.	6.5	5

#	ARTICLE	IF	CITATIONS
73	Multiple anaemic macules and diffuse erythrocytosis revealing mixed cryoglobulinaemia. <i>European Journal of Dermatology</i> , 2011, 21, 269-270.	0.6	5
74	Scalp vein thrombosis mimicking giant cell arteritis relapse. <i>Internal Medicine Journal</i> , 2011, 41, 492-495.	0.8	4
75	T Lymphocyte Plasticity in Autoimmunity and Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-2.	1.9	4
76	T-cell immune response predicts the risk of critical SARS-Cov2 infection in hospitalized COVID-19 patients. <i>European Journal of Internal Medicine</i> , 2022, 102, 104-109.	2.2	4
77	Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with giant cell arteritis? Comment on the paper of Espigol-Frigoleet al. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, e3-e3.	0.9	3
78	Oxaliplatin-Induced Evans Syndrome: A Possible Dual Mechanism. <i>Clinical Colorectal Cancer</i> , 2020, 19, 57-60.	2.3	3
79	Immune Thrombocytopenia Revealing Enriched IgG-4 Peri-Renal Rosai-Dorfman Disease Successfully Treated with Rituximab: A Case Report and Literature Review.. <i>Frontiers in Medicine</i> , 2021, 8, 678456.	2.6	3
80	A Multicenter Study Evaluating the Safety of Romiplostim at Maximal Dosage for Emergency Bleeding Situations in Immune Thrombocytopenia. <i>Blood</i> , 2016, 128, 2541-2541.	1.4	3
81	Thrombopoietin-Receptor Agonist in Systemic Lupus Erythematosus Associated Immune Thrombocytopenia: Results of the 16 Patients from the French Cohort. <i>Blood</i> , 2016, 128, 2542-2542.	1.4	3
82	Physiopathologie des artérites à cellules géantes. <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 215-222.	0.0	2
83	Anti-Mi2 dermatomyositis revisited: pure DM phenotype with muscle fiber necrosis and high risk of malignancy. <i>Neuromuscular Disorders</i> , 2017, 27, S153.	0.6	2
84	Adrenal Insufficiency Revealing a Bilateral Adrenal Hemorrhage-Adrenal Infarction Related to Antiphospholipid Syndrome. <i>American Journal of Medicine</i> , 2022, 135, 194-195.	1.5	2
85	Safety and Efficacy Of Rituximab In adult's Immune Thrombocytopenia (ITP) : Results After One-Year Of Follow-Up In 252 Patients From The Prospective French ITP-Ritux Registry. <i>Blood</i> , 2013, 122, 450-450.	1.4	2
86	A Multicenter, Case-Control Study Evaluating the Characteristics and Outcome of ITP Patients Refractory to, Rituximab, Splenectomy and Both TPO Receptor Agonists. <i>Blood</i> , 2015, 126, 3460-3460.	1.4	2
87	Human Monocyte-Derived Suppressor Cell Supernatant Induces Immunoregulatory Effects and Mitigates xenoGvHD. <i>Frontiers in Immunology</i> , 2022, 13, 827712.	4.8	2
88	P.14.2 Dermatomyositis associated with MDA-5 antibodies: Report of the first European series. <i>Neuromuscular Disorders</i> , 2013, 23, 813-814.	0.6	1
89	Reply. <i>Arthritis and Rheumatism</i> , 2013, 65, 1134-1135.	6.7	1
90	Does Tocilizumab Indeed Reduce the Frequency of Th17 Cells? Comment on the Article by Thiolat et al. <i>Arthritis and Rheumatology</i> , 2014, 66, 2639-2640.	5.6	1

#	ARTICLE	IF	CITATIONS
91	A great masquerader disease . European Journal of Internal Medicine, 2020, 78, 133-134.	2.2	1
92	Switching From Romiplostim to Eltrombopag or Vice Versa for Immune Thrombocytopenia: Efficacy and Safety in 46 Patients. Blood, 2012, 120, 4651-4651.	1.4	1
93	Emergence of Long-Lived Autoreactive Plasma Cells in the Spleen of Primary Warm Auto-Immune Hemolytic Anemia Patients Treated with Rituximab. Blood, 2014, 124, 569-569.	1.4	1
94	A Multi-Centre Randomized and Double-Blind Controlled Trial of Rituximab for Warm Autoimmune Hemolytic Anemia in Adults. Blood, 2015, 126, 3338-3338.	1.4	1
95	High Incidence of Venous Thromboembolism Events during Warm Autoimmune Hemolytic Anemia. Blood, 2016, 128, 2448-2448.	1.4	1
96	Cost Effectiveness of Rituximab Given At Fixed Dose (1000 mg on days 1 and 15) Compared to the Standard Regimen in adult's Immune Thrombocytopenia.. Blood, 2012, 120, 2157-2157.	1.4	1
97	Failure of Rituximab in Immune Thrombocytopenia Is Associated with the Activation of Splenic CD8 T Cells. Blood, 2012, 120, 623-623.	1.4	1
98	Efficacy and Safety of a Combination of Thrombopoietin Receptor Agonist with an Immunosuppressant Therapy for the Management of Multirefractory Adult ITP: Results from a Retrospective, Multicenter, Observational Study. Blood, 2020, 136, 12-13.	1.4	1